共 50 条
- [1] A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative hormone receptor-positive breast cancer and bone metastasesANNALS OF ONCOLOGY, 2016, 27Rugo, H.Petrenciuc, O.Zhang, A.Li, R.Coleman, R. E.
- [2] A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative hormone receptor-positive breast cancer and bone metastases.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Rugo, Hope S.Li, RuiPetrenciuc, OanaZhang, AmilyColeman, Robert E.
- [3] A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride in HER2-negative, hormone receptor-positive breast cancer patients with bone metastasesCANCER RESEARCH, 2017, 77Coleman, R. E.Fried, G.Petrenciuc, O.Sawhney, A.Li, R.Rugo, H. S.
- [4] A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in human epidermal growth factor receptor 2 negative, hormone receptor-positive breast cancer patients with bone metastasesCANCER RESEARCH, 2016, 76Rugo, H. S.Huang, L.Petrenciuc, O.Zaccarini, P.Coleman, R. E.
- [5] A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy ± radium-223 dichloride in human epidermal growth factor receptor 2-negative, hormone receptor-positive breast cancer patients with bone metastasesCANCER RESEARCH, 2016, 76Coleman, R. E.Huang, L.Petrenciuc, O.Zaccarini, P.Rugo, H. S.
- [6] A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride (Ra-223) in HER2- hormone receptor+ breast cancer patients with bone metastases.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Coleman, Robert E.Li, RuiSawhney, Amrita G.Petrenciuc, OanaRugo, Hope S.
- [7] A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy (HT) ± radium-223 dichloride (Ra-223) in HER2- hormone receptor+ breast cancer patients (pts) with bone metastases (mets).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Coleman, Robert E.Huang, LipingPetrenciuc, OanaZaccarini, Paola
- [8] Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trialsBreast Cancer Research and Treatment, 2024, 204 : 249 - 259Hope S. RugoCatherine H. Van PoznakPatrick NevenIwona DanielewiczSoo Chin LeeMario CamponeJeannie Y. K. ChikEstela Vega AlonsoBjørn NaumeEtienne BrainJonathan M. SiegelRui LiDeise UemaVolker J. WagnerRobert E. Coleman
- [9] Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trialsBREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (02) : 249 - 259Rugo, Hope S.Van Poznak, Catherine H.Neven, PatrickDanielewicz, IwonaLee, Soo ChinCampone, MarioChik, Jeannie Y. K.Alonso, Estela VegaNaume, BjornBrain, EtienneSiegel, Jonathan M.Li, RuiUema, DeiseWagner, Volker J.Coleman, Robert E.
- [10] XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral diseaseBreast Cancer Research, 25Peter SchmidJavier CortesAna JoaquimNoelia Martínez JañezSerafín MoralesTamara Díaz-RedondoSibel BlauPatrick NevenJulie LemieuxJosé Ángel García-SáenzLowell HartTsvetan BiyukovNavid BaktashDan MasseyHoward A. BurrisHope S. Rugo